MyVisionTest News Archive

Displaying news items tagged with Macugen (More tags »)
SELECT PAGE
First <<  1 2 3   >> Last

Intravitreal injection
Jan 14, 2012
Elevated intraocular pressure (IOP) after an intravitreal injection of anti-vascular endothelial growth factor (VEGF) agents for age-related macular degeneration (AMD) is not uncommon, but this study failed to identify any significant risk factors for its occurrence. Studies investigating transient increases in intraocular pressure (IOP)...

Full Article


Diabetes
Mar 27, 2011
The National electronic Library for Medicines in the European Union (EU) has published a review that summarizes the clinical trial data investigating the safety and effectiveness of Lucentis, Macugen, and Iluvien in the treatment of diabetic macular edema. Diabetic macular edema (DME) is a common manifestation of diabetic retinopathy and can...

Full Article


Children
Feb 27, 2011
Anti-VEGF drugs were safe and effective in the treatment of choroidal neovascular membranes (CNVMs) secondary to a variety of etiologies in 4 children, according to a new study. In the pediatric population, the diagnosis and management of choroidal neovascular membranes (CNVM) is challenging. Pediatric CNVMs are an infrequent but significant...

Full Article


Intravitreal injection
May 3, 2010
Anterior chamber paracentesis prior to intravitreal Macugen (pegaptanib) injection prevents elevation of intraocular pressure (IOP) elevation following injection. Elevation of IOP is a risk factor for glaucoma. IOP reflects a balance between the rate that fluid flows into the eye and the rate that it exits the eye. If inflow increases or...

Full Article


Feb 17, 2010
Maugen (pegaptanib sodium) is effective in real-world patients with treatment-naive neovascular age-related macular degeneration (NV-AMD) in uncontrolled community-based retina practices, according to a new study. Anti-VEGF treatments, such as pegaptanib sodium (Macugen), ranibizumab (Lucentis) and bevacizumab (Avastin), are the first...

Full Article


Intravitreal injection
Nov 18, 2009
Vascular endothelial growth factor (VEGF) ligands and their receptors are essential for development and for a wide variety of physiologic functions through adulthood, including visual function. Given the ubiquitous physiologic role of VEGF, evaluation of potential safety risks associated with nonspecific inhibition of VEGF-A and other VEGF-related...

Full Article


Oct 23, 2009
Intravitreal Macugen (pegaptanib) is effective in causing regression of proliferative diabetic retinopathy, according to a new study. The Isoform 165 of VEGF-A (VEGF-165) is potent in promoting ocular neovascularisation and breakdown of the blood–retinal barrier (BRB) through a leucocyte-dependent mechanism. Pegaptanib sodium is a selective...

Full Article


Macugen
Aug 16, 2009
A retrospective chart review finds that intravitreal Macugen (pegaptanib sodium) is effective in the treatment of patients with diabetic macular edema (DME). This study involved a retrospective outcome analysis, by optical coherence tomography (OCT) and best-corrected visual acuity (BCVA), of eyes with DME treated with intravitreal Macugen....

Full Article


Avastin
Jul 16, 2009
A study on rabbits finds that intravitreal injection of Avastin (bevacizumab) and Macugen (pegaptanib sodium) caused a significant increase in apoptotic activity (cell death) in photoreceptor cells. Avastin, but not Macugen, demonstrated greater apoptotic activity at higher doses. Avastin is an anti-VEGF humanized monoclonal antibody that...

Full Article


Intravitreal injection
Jun 24, 2009
A new study reporting on the largest series of presumed endophthalmitis cases following intravitreal anti-VEGF injection published to date finds an incidence of 0.049%, and that 20% of cases have a very poor visual outcome. Endophthalmitis is the most dreaded complication of intravitreal injection. Several studies have reported on the incidence...

Full Article


SELECT PAGE
First <<  1 2 3   >> Last
Most Popular
Less - past - More